AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26256065 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine, 5 mg daily; Citalopram, 20 mg daily
Number of subjects: 70
Study 26256065 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine, 5 mg daily
Number of subjects: 70
Study 23146744 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle intervention (nine monthly goal-setting telephone calls to patients and support planning calls to spouses)
Number of subjects: 255
Study 23146744 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle intervention
Number of subjects: 255
Study 23146744 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 255
Study 22048601 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved third molar (Group I)
Number of subjects: 54
Study 22048601 — intervention group
Group type: COMPARATOR
Intervention: Extracted third molar (Group II)
Number of subjects: 54
Study 17430467 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ABT)
Number of subjects: 35
Study 17430467 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (HBT)
Number of subjects: 35
Study 17430467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 15073471 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg once daily for 8 weeks
Number of subjects: 193
Study 15073471 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg once daily for 8 weeks
Number of subjects: 193
Study 15073471 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg once daily for 8 weeks
Number of subjects: 193
Study 15073471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 11932279 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (90 mg orally/d)
Number of subjects: 43
Study 11932279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9803690 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting program intervention
Number of subjects: 394
Study 9803690 — intervention group
Group type: COMPARATOR
Intervention: Control condition (regular Head Start program)
Number of subjects: 394
Study 7640316 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume hypocaloric continuous feedings (1 ml/kg/h), beginning at 24 h of age
Number of subjects: 29
Study 7640316 — intervention group
Group type: COMPARATOR
Intervention: NPO group (standard intravenous fluid and nutrition, nothing per OS)
Number of subjects: 29
Study 7640316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 2680286 — intervention group
Group type: EXPERIMENTAL
Intervention: co-dergocrine mesylate (3 mg daily intravenous infusion over 14 days)
Number of subjects: 40
Study 2680286 — intervention group
Group type: COMPARATOR
Intervention: placebo (intravenous infusion over 14 days)
Number of subjects: 40
Study 2680286 — intervention group
Group type: EXPERIMENTAL
Intervention: co-dergocrine mesylate
Number of subjects: 40
Study 2680286 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 187313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Number of subjects: 118
Study 187313 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Number of subjects: 118
Study 187313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment in patients with anaplastic small cell carcinoma
Number of subjects: 118
Study 187313 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment in patients with anaplastic small cell carcinoma
Number of subjects: 118
Study 187313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment in patients with epidermoid carcinoma
Number of subjects: 118
Study 187313 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment in patients with epidermoid carcinoma
Number of subjects: 118
Study 187313 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with continued four-drug polychemotherapy
Number of subjects: 118
Study 30710211 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral administration of 4.5 g of arginine and 10 g of glutamine per day for 7 days prior to surgery
Number of subjects: 40
Study 30710211 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 40
Study 30838883 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) favoring the experimental arm
Number of subjects: 207
Study 30838883 — intervention group
Group type: COMPARATOR
Intervention: Clinician-reported adverse events (AEs) favoring the control arm
Number of subjects: 207
Study 30838883 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance between PROs and AEs
Number of subjects: 207
Study 28844330 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 129
Study 28844330 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study 25159626 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLaST© trainer (pattern cutting task)
Number of subjects: 55
Study 25159626 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLaST© trainer (ligating loop task)
Number of subjects: 55
Study 25159626 — intervention group
Group type: COMPARATOR
Intervention: FLS trainer
Number of subjects: 55
Study 25159626 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLaST© trainer
Number of subjects: 55
Study 23276454 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 75
Study 21649817 — intervention group
Group type: EXPERIMENTAL
Intervention: Uma Jeunesse®
Number of subjects: 17
Study 21649817 — intervention group
Group type: COMPARATOR
Intervention: Juvéderm®
Number of subjects: 17
Study 19086236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 911
Study 19086236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 911
Study 19086236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 19086236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan (both doses) in PCA group (n = 317)
Number of subjects: 911
Study 19086236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan (both doses) in non-PCA group (n = 318)
Number of subjects: 911
Study 16436145 — intervention group
Group type: EXPERIMENTAL
Intervention: White sesame seed extract
Number of subjects: 32
Study 16436145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleosins (15 and 17 kDa)
Number of subjects: 32
Study 16436145 — intervention group
Group type: COMPARATOR
Intervention: Detection tests based on sesame vicillins or other storage proteins
Number of subjects: 32
Study 15448528 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation of humidified carbon dioxide
Number of subjects: 0
Study 15448528 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation of dry carbon dioxide
Number of subjects: 0
Study 15448528 — intervention group
Group type: COMPARATOR
Intervention: Control (no insufflation)
Number of subjects: 0
Study 15448528 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation of dry and humidified air
Number of subjects: 0
Study 11264626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education intervention
Number of subjects: 206
Study 11264626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 206
Study 9829446 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream
Number of subjects: 0
Study 9829446 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 7853733 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol infusion (19 eyes)
Number of subjects: 56
Study 7853733 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine infusion (15 eyes)
Number of subjects: 56
Study 7853733 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS) infusion (control, 22 eyes)
Number of subjects: 56
Study 2780127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 12
Study 2780127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg methylphenidate
Number of subjects: 12
Study 2780127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 3098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockers (practolol, H 87/07, metoprolol)
Number of subjects: 54
Study 3098 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54
Study 30311686 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics
Number of subjects: 41
Study 30311686 — intervention group
Group type: COMPARATOR
Intervention: Routine non-invasive tests
Number of subjects: 41
Study 29216250 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy (RY)
Number of subjects: 40
Study 29216250 — intervention group
Group type: COMPARATOR
Intervention: Billroth-I reconstruction (BI)
Number of subjects: 40
Study 26140943 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted HDL (rHDL) 40 mg/kg
Number of subjects: 40
Study 26140943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23268367 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg tabalumab
Number of subjects: 100
Study 23268367 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg tabalumab
Number of subjects: 100
Study 23268367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tabalumab group
Number of subjects: 100
Study 23268367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20961333 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid withdrawal (prednisone)
Number of subjects: 0
Study 20961333 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid continuation (prednisone)
Number of subjects: 0
Study 19441606 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 110 microg once daily
Number of subjects: 474
Study 19441606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 17195934 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-stabilized orthesis with prescribed full weight bearing after the second week (OG)
Number of subjects: 45
Study 17195934 — intervention group
Group type: COMPARATOR
Intervention: Functional aftertreatment with partial weight bearing of 15 kg for 6 weeks (CG)
Number of subjects: 45
Study 15633326 — intervention group
Group type: COMPARATOR
Intervention: Normal expanded polytetrafluoroethylene (ePTFE) membrane (NM)
Number of subjects: 10
Study 15633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ePTFE membrane (MM)
Number of subjects: 10
Study 11350640 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cotton gauze (oxidized, sulfonated, phosphorylated)
Number of subjects: 0
Study 11350640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialdehyde cotton gauze
Number of subjects: 0
Study 11350640 — intervention group
Group type: COMPARATOR
Intervention: Untreated cotton gauze
Number of subjects: 0
Study 9393281 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 resection
Number of subjects: 711
Study 7956499 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (normothermic group)
Number of subjects: 20
Study 7956499 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid (hypothermic group)
Number of subjects: 20
Study 3652756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 29
Study 3652756 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice with arterial blood gas measurements
Number of subjects: 29
Study 31351460 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A training
Number of subjects: 48
Study 31351460 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC training
Number of subjects: 48
Study 29374382 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day zinc supplementation
Number of subjects: 28
Study 29374382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27639853 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod (0.6 mg/d)
Number of subjects: 0
Study 27639853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24850280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (10 weeks, double-blind, placebo-controlled)
Number of subjects: 81
Study 24850280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 weeks, double-blind, placebo-controlled)
Number of subjects: 81
Study 22236222 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial tachyarrhythmias detected by implanted devices (occurring in 261 patients, 10.1%)
Number of subjects: 2580
Study 22236222 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial tachyarrhythmias detected by implanted devices
Number of subjects: 2580
Study 22236222 — intervention group
Group type: COMPARATOR
Intervention: Continuous atrial overdrive pacing
Number of subjects: 2580
Study 22236222 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial tachyarrhythmias
Number of subjects: 2580
Study 19283648 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group sessions in addition to psychiatric treatment as usual (TAU)
Number of subjects: 28
Study 19283648 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric treatment as usual (TAU) without group sessions
Number of subjects: 28
Study 17229079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low‐dose CsA (target trough levels of 50‐100 ng/mL), weaned from month 4 and withdrawn by month 6
Number of subjects: 536
Study 17229079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab, MMF, CS and low‐dose CsA
Number of subjects: 536
Study 17229079 — intervention group
Group type: COMPARATOR
Intervention: MMF, CS and standard‐dose CsA
Number of subjects: 536
Study 17229079 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA withdrawal group
Number of subjects: 536
Study 17229079 — intervention group
Group type: COMPARATOR
Intervention: Low‐dose CsA group
Number of subjects: 536
Study 17229079 — intervention group
Group type: COMPARATOR
Intervention: Standard‐dose CsA group
Number of subjects: 536
Study 15820814 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A)
Number of subjects: 120
Study 15820814 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus placebo tablets (group B)
Number of subjects: 120
Study 15820814 — intervention group
Group type: COMPARATOR
Intervention: Injection of a placebo solution plus placebo tablets (group C)
Number of subjects: 120
Study 12212781 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone daily for 6 months
Number of subjects: 0
Study 12212781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9797627 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning regimen CPAP for 72 hours (n = 29)
Number of subjects: 58
Study 9797627 — intervention group
Group type: COMPARATOR
Intervention: Rescue regimen CPAP (n = 29)
Number of subjects: 58
Study 8564348 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 30 mg
Number of subjects: 38
Study 8564348 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 45 mg
Number of subjects: 38
Study 8564348 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 60 mg
Number of subjects: 38
Study 8564348 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of response rates in three therapeutic groups
Number of subjects: 38
Study 2523525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 5 micrograms doses of Engerix B recombinant DNA hepatitis B vaccine
Number of subjects: 215
Study 2523525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10 micrograms doses of Engerix B recombinant DNA hepatitis B vaccine
Number of subjects: 215
Study 58198 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus droperidol
Number of subjects: 158
Study 58198 — intervention group
Group type: COMPARATOR
Intervention: Atropine plus diazepam
Number of subjects: 158
Study 58198 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 158
Study 31277138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib combined with chemotherapy
Number of subjects: 100
Study 31277138 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 100
Study 31277138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib combined with chemotherapy (for COX-2 positive patients)
Number of subjects: 100
Study 29276907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (6.9±2.2 mg/day, n=25)
Number of subjects: 49
Study 29276907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (162.5±46.2 mg/day, n=24)
Number of subjects: 49
Study 25115995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Sodium hypochlorite (NaOCl) used as a cleansing agent in pulpotomy procedures
Number of subjects: 128
Study 25115995 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) as pulpotomy material
Number of subjects: 128
Study 25115995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) as pulpotomy material
Number of subjects: 128
Study 25115995 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline used as a cleansing agent in pulpotomy procedures
Number of subjects: 128
Study 24810309 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 30
Study 24810309 — intervention group
Group type: COMPARATOR
Intervention: Skin graft
Number of subjects: 30
Study 23055504 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint motion/disparity grating
Number of subjects: 0
Study 23055504 — intervention group
Group type: COMPARATOR
Intervention: Pure disparity gratings
Number of subjects: 0
Study 18514464 — intervention group
Group type: EXPERIMENTAL
Intervention: ATNAA auto-injector
Number of subjects: 56
Study 18514464 — intervention group
Group type: COMPARATOR
Intervention: Mark I auto-injector
Number of subjects: 56
Study 18514464 — intervention group
Group type: COMPARATOR
Intervention: Traditional needle/syringe
Number of subjects: 56
Study 17466405 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐assisted mediastinoscopy (VAM)
Number of subjects: 359
Study 17466405 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy without VAM (Group A)
Number of subjects: 359
Study 17466405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy with extended dissection of mediastinal lymph nodes (Group C)
Number of subjects: 359
Study 17466405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (stage IA patients)
Number of subjects: 359
Study 17466405 — intervention group
Group type: COMPARATOR
Intervention: Group B (stage IA patients)
Number of subjects: 359
Study 15204273 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail alert occurring 1000 ms before collision warning
Number of subjects: 0
Study 15204273 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail alert occurring 300 ms before collision warning
Number of subjects: 0
Study 15204273 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly urgent sounds
Number of subjects: 0
Study 15204273 — intervention group
Group type: EXPERIMENTAL
Intervention: Annoyance ratings
Number of subjects: 0
Study 15204273 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in rated urgency of collision warnings and e-mail alerts
Number of subjects: 0
Study 15963391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 52
Study 15963391 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 52
Study 15963391 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 52
Study 10516515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5% eye drops
Number of subjects: 0
Study 8969573 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 8969573 — intervention group
Group type: COMPARATOR
Intervention: Short-term placebo-controlled trials
Number of subjects: 0
Study 1882896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g granulate four times daily
Number of subjects: 60
Study 1882896 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 60
Study 1882896 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60
Study 1882896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60
Study 6309542 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (3.5 mg/kg)
Number of subjects: 8
Study 6309542 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (9.5 mg/kg)
Number of subjects: 8
Study 30634195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume bowel preparation (0.3L sodium picosulfate with magnesium citrate)
Number of subjects: 13497
Study 30634195 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume bowel preparation (4L polyethylene glycol)
Number of subjects: 13497
Study 29274618 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (TAS-102)
Number of subjects: 800
Study 29274618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 25731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 54
Study 25731653 — intervention group
Group type: COMPARATOR
Intervention: Control (immediate clamping)
Number of subjects: 54
Study 24330449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block (15 mL of 0.25% Bupivacaine plus 5 μ/ml epinephrine)
Number of subjects: 44
Study 24330449 — intervention group
Group type: COMPARATOR
Intervention: Saline TAP block (control group)
Number of subjects: 44
Study 24330449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block
Number of subjects: 44
Study 22329791 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference pairs (COTTON-PRINT)
Number of subjects: 0